




Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lncn19>

Development of Novel Bridged and Caged Nucleoside Analogs as Biochemical Tools

Michael P. Groziak^a & Ronghui Lin^a

^a Department of Chemistry and Biochemistry, Southern Illinois University, Carbondale, IL, 62901-4409, USA

Published online: 16 Aug 2006.

To cite this article: Michael P. Groziak & Ronghui Lin (1997) Development of Novel Bridged and Caged Nucleoside Analogs as Biochemical Tools, *Nucleosides and Nucleotides*, 16:7-9, 1419-1421, DOI: [10.1080/07328319708006196](https://doi.org/10.1080/07328319708006196)

To link to this article: <http://dx.doi.org/10.1080/07328319708006196>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.


This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

DEVELOPMENT OF NOVEL BRIDGED AND CAGED NUCLEOSIDE ANALOGS AS BIOCHEMICAL TOOLS

Michael P. Groziak* and Ronghui Lin, Department of Chemistry and Biochemistry,
Southern Illinois University, Carbondale, IL 62901-4409 USA

Abstract: New classes of closely biomimetic, *anti* conformation restricted, transglycosidic spiro, bridged, and caged pyrimidine nucleoside analogs are being developed. Progress towards accessing members of the new caged 2'-deoxyuridine mimic class is related.


Of the many classes of transglycosidic cyclonucleoside analogs developed as bioactive or medicinal agents or as biochemical tools for conformation/bioactivity relationship studies, few are spiro or caged in nature and many are substantially different in structure by comparison to natural counterparts. The uridine-6-carboxaldehydes **1a-d**¹⁻³ are so highly electrophilic that, save for **1d**, each exhibits a strong proclivity towards adopting transglycosidic hemiacetal forms. In our laboratory, we are developing spiro nucleosides **3a-d** from **2a,b**, mono-bridged 5'-epimeric diastereomers **4a,b** from **3d**, and caged 2'-deoxyuridine mimics **5a-c** from **1c** and its 5' carboxaldehyde derivative. Access to targets **3a-d**, **4a-b**, and **5b,c** are all based on the chemistry of nucleoside 5'-carboxaldehydes, known to undergo hydrate and hemiacetal formation upon exposure to water or alcohol.⁴



Whereas its unprotected counterpart (**2**, $R_1=R_2=H$, $R_3=CHO$) forms only a dihydrate in water, **2a** forms spiro **3a** *via* intramolecular Michael-type addition.^{5,6} Aldehyde **2b** likewise forms **3c**.⁷ When acetylated, **3d** affords bridged **4a**,⁷ now being processed to **4b**.

RESULTS AND DISCUSSION

To our knowledge, the classes of transglycosidic-bridged nucleosides^{8,9} contain only one subclass of caged compounds.¹⁰ In a recent advancement towards accessing the novel caged 2'-deoxyuridine mimics **5c**, we have recently completed a synthesis of a methoxy-bearing **5b**. 1,3-Diphenylimidazolidine (DPI) **6**, obtained (86%) from its corresponding aldehyde, led to **7** (31%) together with its 3'-phenyl carbonate (58%) under 2,2'-anhydro forming conditions. Saponification of either of these gave the O²,6-cyclic intermediate **8**. Deprotection (100%) at the 6-position of the dihydrouracil ring of **8** gave hydrate **9**. In a key step for subsequent cage construction, hydrate **9** reverted to **10** (100%) simply upon desiccation. As does **5c**,^{6b,c} **10** exists as a 3:1 mixture of hemiacetal diastereomers. Deprotection of **10** was sluggish but proceeded (60%) to give a 2:1 diastereomeric mixture of 7,02'-cyclic hemiacetals rather than **5c**. Attempts to link the 7-hemiacetal OH group with the 5'-carbonyl one in the 7,02'-cyclic hemiacetals to **5c** have thus far been unsuccessful. However, an intramolecular acetal formation mediated by TsOH in 1:2 DMA/benzene afforded **5b**,¹¹ isolated as a single diastereomer in a 25% yield. Efforts are now underway to effect demethylation of this to **5c**, the unprotected caged nucleoside.



Acknowledgments. RL (present address: Department of Chemistry, University of California at Berkeley) acknowledges receipt of a 1995-1996 Dissertation Research Award Fellowship from the Graduate School at Southern Illinois University.

REFERENCES

1. Groziak, M. P.; Koohang, A. *J. Org. Chem.* **1992**, *57*, 940.
2. Groziak, M. P.; Koohang, A.; Stevens, W. C.; Robinson, P. D. *J. Org. Chem.* **1993**, *58*, 4054.
3. Groziak, M. P.; Lin, R.; Stevens, W. C.; Wotring, L. L.; Townsend, L. B.; Balzarini, J.; Witvrouw, M.; De Clercq, E. *Nucleosides Nucleotides* **1996**, *15*, 1041.
4. (a) Jones, G. H.; Taniguchi, M.; Tegg, D.; Moffatt, J. G. *J. Org. Chem.* **1979**, *44*, 1309. (b) Jones, G. H.; Moffatt, J. G. *J. Am. Chem. Soc.* **1968**, *90*, 5337.
5. Groziak, M. P.; Lin, R. 209th National Meeting of the American Chemical Society, ORGN Division, 1995, Anaheim, CA, Abstr. 180.
6. Groziak, M. P.; Lin, R.; Robinson, P. D. *Acta Cryst.* **1995**, *C51*, 1204.
7. Groziak, M. P.; Lin, R. unpublished results.
8. For representative examples, see (a) Otter, B. A.; Patil, S. A.; Spada, M. R.; Jelicks, L. A.; Yoshimura, Y.; Matsuda, A.; Klein, R. S. *Nucleosides Nucleotides* **1992**, *11*, 615. (b) Megati, S.; Ealick, S. E.; Naguib, F. N. M.; el Kounil, M. H.; Klein, R. S.; Otter, B. A. *Nucleosides Nucleotides* **1994**, *13*, 2151.
9. Ueda, T. *Nucleosides Nucleotides* **1985**, *4*, 67, and references contained therein.
10. (a) Maruyama, T.; Kimura, S.; Sato, Y.; Honjo, M. *J. Org. Chem.* **1983**, *48*, 2719. (b) Maruyama, T.; Kimura, S.; Sato, Y.; Honjo, M. *J. Org. Chem.* **1986**, *51*, 3623.
11. Characterization data for **5b**: ¹H NMR ((CD₃)₂SO) δ 11.5 (1, br, NH), 6.37 (1, d, H1', ³J_{1',2'} = 6.4 Hz), 5.83 and 5.77 (each 1, each s, H5 and H7), 5.71 (1, d, 3'-OH, ³J_{3',3'-OH} = 4.3 Hz), 4.93 (1, d, H5', ³J_{4',5'} = 3.8 Hz), 4.67 (1, d, H2'), 4.38 (1, d, H3'), 4.21 (1, d, H4'), 3.23 (3, s, CH₃O). ¹³C NMR ((CD₃)₂SO) δ 162.4 (C4), 150.8 and 149.1 (C2/C6), 99.4 and 99.2 (C5'/C5), 88.0 (C7), 83.1 (C4'), 79.7 (C1'), 76.7 and 76.4 (C2'/C3'), 55.3 (CH₃O). LRFAB-MS, *m/e* 285.1 (40%, MH⁺). HRFAB-MS (C₃₃H₃₃N₄O₈): calcd 285.0723, found 285.0722.